| Literature DB >> 27131830 |
Ziv Gan-Or1, Noreen Mohsin2, Simon L Girard3, Jacques Y Montplaisir4, Amirthagowri Ambalavanan5, Stephanie Strong2, Victoria Mallett2, Sandra B Laurent2, Cynthia V Bourassa2, Michel Boivin6, Melanie Langlois7, Isabelle Arnulf8, Birgit Högl9, Birgit Frauscher9, Christelle Monaca10, Alex Desautels11, Jean-François Gagnon12, Ronald B Postuma13, Patrick A Dion14, Yves Dauvilliers15, Nicolas Dupre7, Roy N Alcalay16, Guy A Rouleau17.
Abstract
The MC1R gene, suggested to be involved in Parkinson disease (PD) and melanoma, was sequenced in PD patients (n = 539) and controls (n = 265) from New York, and PD patients (n = 551), rapid eye movement sleep behavior disorder (RBD) patients (n = 351), and controls (n = 956) of European ancestry. Sixty-eight MC1R variants were identified, including 7 common variants with frequency > 0.01. None of the common variants was associated with PD or RBD in the different regression models. In a meta-analysis with fixed-effect model, the p.R160W variant was associated with an increased risk for PD (odds ratio = 1.22, 95% confidence interval = 1.02-1.47, p = 0.03) but with significant heterogeneity (p = 0.048). Removing one study that introduced the heterogeneity resulted in nonsignificant association (odds ratio = 1.11, 95% confidence interval, 0.92-1.35, p = 0.27, heterogeneity p = 0.57). Rare variants had similar frequencies in patients and controls (10.54% and 10.15%, respectively, p = 0.75), and no cumulative effect of carrying more than one MC1R variant was found. The present study does not support a role for the MC1R p.R160W and other variants in susceptibility for PD or RBD.Entities:
Keywords: Genetics; MC1R; Melanoma; Parkinson disease
Mesh:
Substances:
Year: 2016 PMID: 27131830 PMCID: PMC4892956 DOI: 10.1016/j.neurobiolaging.2016.03.029
Source DB: PubMed Journal: Neurobiol Aging ISSN: 0197-4580 Impact factor: 4.673